RNA

OliX Pharmaceuticals to Present at Global RNAi-Based Therapeutics Summit

Thursday, July 9, 2020 - 1:00pm

He will also present the advantages of Cell-Penetrating Asymmetric Interfering RNA (cp-asiRNA), OliX Pharmaceuticals proprietary RNAi delivery method that efficiently silences gene expressions which can be locally administered to target various diseases with unmet needs.

Key Points: 
  • He will also present the advantages of Cell-Penetrating Asymmetric Interfering RNA (cp-asiRNA), OliX Pharmaceuticals proprietary RNAi delivery method that efficiently silences gene expressions which can be locally administered to target various diseases with unmet needs.
  • OliX Pharmaceuticals is a clinical stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating expression of disease-causing genes, based on its own proprietary RNAi technology.
  • In comparison to existing siRNA therapeutics, OliX Pharmaceuticals asiRNA shows comparable gene silencing and significantly reduce siRNA-mediated side effects such as off-target gene silencing and immune stimulation.
  • In March 2020, OliX Pharmaceuticals secured a proprietary N-Acetylgalactosamine (GalNac) platform, a RNAi therapy platform that targets variety of liver diseases.

Ionis Pharmaceuticals to hold neurology franchise webcast

Tuesday, July 7, 2020 - 12:05pm

A webcast replay will be available for a limited time at the same address.

Key Points: 
  • A webcast replay will be available for a limited time at the same address.
  • As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective.
  • Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs.
  • To learn more about Ionis visit www.ionispharma.com and follow us on twitter @ionispharma.

Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory Board

Wednesday, July 1, 2020 - 1:00pm

Renowned experts in virology, infectious disease, vaccine development and public health to support Arcturus COVID-19 vaccine program, LUNAR-COV19

Key Points: 
  • Renowned experts in virology, infectious disease, vaccine development and public health to support Arcturus COVID-19 vaccine program, LUNAR-COV19
    SAN DIEGO, July 01, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc.(the Company, Arcturus, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced the formation of its Vaccine Platform Scientific Advisory Board (SAB) comprised of world-leading experts in the fields of virology, infectious disease, vaccine development and public health.
  • We are proud to have such an accomplished and diverse group of scientific, clinical and public policy experts joining our Scientific Advisory Board.
  • I look forward to working closely with our SAB members to bring our promising vaccine approach forward to help address this global public health crisis.
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.

DGAP-News: Publication in PNAS unveils molecular pathway required for influenza virus replication with large potential as an antiviral drug target

Tuesday, June 30, 2020 - 2:10pm

[1] , [2] The research identifies and confirms the full molecular chain of events connecting the virus-activated Raf/MEK/ERK signalling pathway via its downstream target RSK to the final export of vRNPs during an influenza virus infection.

Key Points: 
  • [1] , [2] The research identifies and confirms the full molecular chain of events connecting the virus-activated Raf/MEK/ERK signalling pathway via its downstream target RSK to the final export of vRNPs during an influenza virus infection.
  • As the virus is unable to perform this function by itself, this represents an Achilles heel of virus replication.
  • [3]
    "By targeting the enzyme MEK, an essential component of the signalling cascade, ATR-002 inhibits this pathway and, thus, leads to a blockade of viral replication.
  • This pathway is central for replication of many RNA viruses, such as the influenza virus, hantavirus or respiratory syncytial virus (RSV) and also SARS-CoV-2, the virus that causes COVID-19.

Arcturus Therapeutics to be Added to Russell 2000® Index

Monday, June 29, 2020 - 1:00pm

SAN DIEGO, June 29, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc.(the Company, Arcturus, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced thatit will be added to the Russell 2000Index, as part of the 2020 Russell indexes reconstitution.

Key Points: 
  • SAN DIEGO, June 29, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc.(the Company, Arcturus, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced thatit will be added to the Russell 2000Index, as part of the 2020 Russell indexes reconstitution.
  • FTSE Russell index expertise and products are used extensively by institutional and retail investors globally.
  • FTSE Russell is focused on index innovation and customer partnership applying the highest industry standards and embracing the IOSCO Principles.
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.

Assessment of COVID-19's Effect on the Global RNAi Technology Market 2020-2024 | Adoption Of RNAi Technology For Undruggable Targets to Augment Growth | Technavio

Wednesday, June 24, 2020 - 12:15am

The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Key Points: 
  • The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
  • While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities.
  • Technavios in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis.
  • The adoption of RNAi technology for undruggable targets has been instrumental in driving the growth of the market.

HTG EdgeSeq Technology Highlighted in Multiple Posters Presented by Pharma Partners at the 2020 American Association for Cancer Research Virtual Meeting

Tuesday, June 23, 2020 - 9:01pm

TUCSON, Ariz., June 23, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced its HTG EdgeSeq technology was highlighted in multiple posters presented by global pharma company partners at the American Association for Cancer Research (AACR) 2020 Virtual Meeting.

Key Points: 
  • TUCSON, Ariz., June 23, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced its HTG EdgeSeq technology was highlighted in multiple posters presented by global pharma company partners at the American Association for Cancer Research (AACR) 2020 Virtual Meeting.
  • It is very satisfying to see our pharma partners enhancing their research and findings with our HTG EdgeSeq technology, and we look forward to continuing to build on this momentum.
  • Posters presented at the 2020 Virtual AACR meeting using HTG EdgeSeq technology include:
    Comparison of HTG-Edge targeted RNA sequencing platform with whole transcriptome RNA sequencing for clinical biomarker studies; and
    Pan-cancer gene expression analysis of tissue microarray using HTG EdgeSeq Oncology Biomarker Panel and a cross-comparison with ERBB3 immunohistochemical analysis.
  • These posters highlighting our technology at this years AACR conference are a testament to the utility of our technology, said John Lubniewski, President and CEO of HTG.

Personalis to Participate in European Association for Cancer Research (EACR) 2020 Virtual Congress

Thursday, June 18, 2020 - 11:15pm

Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced the companys participation in the European Association for Cancer Research (EACR) 2020 Virtual Congress, which will be held online, June 18-19, 2020.

Key Points: 
  • Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced the companys participation in the European Association for Cancer Research (EACR) 2020 Virtual Congress, which will be held online, June 18-19, 2020.
  • Personalis will present Enabling Composite Biomarker Discovery for Precision Cancer Therapy with an Enhanced Exome and Transcriptome Platform in an industry-sponsored symposium , featuring the Personalis universal cancer immunogenomics platform, ImmunoID NeXT .
  • Erin Newburn, MS, PhD, will present for Personalis.
  • Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patients cancer and immune response.

Alnylam to Host Seventh Annual “RNAi Roundtable” Webcast Series

Thursday, June 18, 2020 - 12:00pm

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 7th annual series of RNAi Roundtable webinars over the coming weeks.

Key Points: 
  • Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 7th annual series of RNAi Roundtable webinars over the coming weeks.
  • The initial 2020 RNAi Roundtable schedule will be as follows:
    Additional RNAi Roundtables will be scheduled over the coming weeks, and will include:
    Please visit the Capella section of our website for the latest information regarding webcast dates.
  • By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines, known as RNAi therapeutics, is now a reality.
  • Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform.

Dicerna Receives Rare Pediatric Disease Designation From U.S. Food and Drug Administration for Nedosiran for Treatment of Primary Hyperoxaluria

Thursday, June 18, 2020 - 12:30pm

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the Company or Dicerna), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the U.S. Food and Drug Administration (FDA or the agency) has granted rare pediatric disease designation for nedosiran, an investigational RNAi therapy being developed as a once-monthly treatment for primary hyperoxaluria (PH).

Key Points: 
  • Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the Company or Dicerna), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the U.S. Food and Drug Administration (FDA or the agency) has granted rare pediatric disease designation for nedosiran, an investigational RNAi therapy being developed as a once-monthly treatment for primary hyperoxaluria (PH).
  • Nedosiran is the Companys lead product candidate and is in development for PH types 1, 2 and 3.
  • The FDAs rare pediatric disease designation for nedosiran for primary hyperoxaluria reflects the agencys continued recognition that PH is a serious and potentially fatal condition, with disease consequences that frequently manifest in childhood but progress over time into adulthood, said Ralf Rosskamp, M.D., chief medical officer at Dicerna.
  • Primary hyperoxaluria (PH) is a family of ultra-rare, life-threatening genetic disorders that initially manifest with complications in the kidneys.